Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1997-04-03
2004-01-13
Wehb′, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023500, C530S350000, C435S320100, C435S455000
Reexamination Certificate
active
06677312
ABSTRACT:
TECHNICAL AREA OF THE INVENTION
The invention relates to the area of cancer diagnostics and therapeutics. More particularly, the invention relates to detection and remediation of the loss and or alteration of wild-type p53 genes from tumor tissues.
BACKGROUND OF THE INVENTION
Recent studies have elucidated several genetic alterations that occur during the development of colorectal tumors, the most common of which are deletions of the short arm of chromosome 17 (17p). While some genetic alterations such as RAS gene mutations, appear to occur relatively early during colorectal tumor development, chromosome 17p deletions are often late events associated with the transition from the benign (adenomatous) to the malignant (carcinomatous) state. See Vogelstein et al., New England Journal of Medicine, Vol. 319, p525, 1988.
Because carcinomas are often lethal, while the precursor adenomas are uniformly curable, the delineation of the molecular events mediating this transition are of considerable importance. The occurrence of allelic deletions of chromosome 17p in a wide variety of cancers besides those of the colon, including those of the breast and lung, further emphasizes the importance of genes residing on chromosome 17p in the neoplastic process. Because allelic deletions have been reported to encompass a large area of chromosome 17p, there is a need in the art for defining the particular genetic region which is responsible for the neoplastic progression.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a method for diagnosing a neoplastic tissue of a human.
It is another object of the invention to provide a method of supplying wild-type p53 gene function to a cell which has lost said gene function.
It is yet another object of the invention to provide a kit for determination of the nucleotide sequence of the p53 gene by using the polymerase chain reaction.
It still another object of the invention to provide a nucleic acid probe for detection of mutations in the human p53 gene.
These and other objects of the invention are provided by one or more of the embodiments which are described below. In one embodiment of the present invention a method of diagnosing a neoplastic tissue of a human is provided comprising: isolating from a human a tissue suspected of being neoplastic; and detecting loss of wild-type p53 genes or their expression products from said tissue, said loss indicating neoplasia of the tissue.
In another embodiment of the present invention a method is provided for supplying wild-type p53 gene function to a cell which has lost said gene function by virtue of a mutation in the p53 gene, comprising: introducing a wild-type p53 gene into a cell which has lost said gene function such that said wild-type gene is expressed in the cell.
In yet another embodiment a kit is provided for determination of the nucleotide sequence of the p53 gene by polymerase chain reaction. The kit comprises: a set of pairs of single stranded DNA primers, said set allowing synthesis of all nucleotides of the p53 gene coding sequences.
In still another embodiment of the invention a nucleic acid probe is provided which is complementary to human wild-type p53 gene sequences and which can form mismatches with mutant p53 genes, thereby allowing their detection by enzymatic or chemical cleavage or by shifts in electrophoretic mobility.
The present invention provides the art with the information that the p53 gene is, in fact, the target of both deletional and point mutational alterations on chromosome 17p which are associated with the process of tumorigenesis. This information allows highly specific assays to be done to assess the neoplastic status of a particular tumor tissue as well as the performance of therapeutic anti-cancer methods.
REFERENCES:
patent: 5087617 (1992-02-01), Smith
patent: 5248671 (1993-09-01), Smith
patent: 5532220 (1996-07-01), Lee et al.
Anderson, W.F. Human Gene Therapy. Nature 392 (Supplement):25-30, Apr. 1998.*
Hodgson, C.P. Advances in Vector Systems for Gene Therapy. Exp. Opin. Ther. Patents 5(5):459-468, 1995.*
Miller, N. et al. Targeted Vectors for Gene Therapy. FASEB Journal 9:190-199, 1995.*
Verma, I.N. Gene Therapy—Promises, Problems and Prospects. Nature 389:239-242, Apr. 1998.*
Frommel, C. et al. An Estimate on the Effect of Point Mutation and Natural Selection on the Rate of Amino Acid Replacement in Proteins. Journal of Molecular Evolution 21:233-257, 1985.*
Ngo, J.T. et al. Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox in The Protein Folding Problem and Tertiary Structure Prediction (Merz, ed.). Birkhauser, Boston, 1994.*
Bowie, J.U. et al. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions. Science 247: 1306-1310, Apr. 1998.*
Marshall, “Less Hype, More Biology Needed for Gene Therapy”, Science, vol. 270, p. 1751, Dec. 1995.
Donahue et al., “Helper Virus Induced T Cell Lymphoma in Nonhuman Primates after Retroviral Mediated Gene Transfer” The Journal of Experimental Medicine, Vol 176, pp. 1125-1135, Oct. 1992.
Marshall, “Gene Therapy's Growing Pains”, Science, vol. 269, pp. 1050-1055, Aug. 1995.
Andy Coghlan, “Gene dream fades away”, Focus, New Scientist, pp. 14-15, Nov. 25, 1995.
Orkin & Motulsky “Report” Recommendations of the panel to assess the NIH investment in research on gene Therapy, Dec. 7, 1995.
Finlay et al. “The p53 Proro-oncogene canact as a suppressor of transopmation”, Cell, vol. 57, pps. 1083-1093, Jun. 30, 1989.
Eliyahu et al., “Wild-type p53 can inhibit oncogene-mediated focus formation” Proc. Natl. Acad. Science USA., Vol 86, pps. 8763-8767, Nov. 1989.
Koshland, “p53 Sweeps Trhough Cancer Research”, Science, 262:1958-1959 (1993).
Baker Suzanne
Fearon Eric R.
Nigro Janice M.
Vogelstein Bert
Banner & Witcoff , Ltd.
The Johns Hopkins University
Wehb′ Anne M.
LandOfFree
Methods for restoring wild-type p53 gene function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for restoring wild-type p53 gene function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for restoring wild-type p53 gene function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3256381